Enhancing hypnotizability and treatment responsiveness.

2004 ◽  
pp. 235-249 ◽  
Author(s):  
Jeffrey D. Gfeller
Keyword(s):  
Treatment Responsiveness

P1-166: Assessing treatment responsiveness of anti-dementia drugs with the SymptomGuide™

2011 ◽  
Vol 7 ◽  
pp. S164-S165
Author(s):  
Kenneth Rockwood ◽  
Arnold Mitnitski ◽  
An Zeng ◽  
Laura Dong Lin
Keyword(s):  
Treatment Responsiveness

scholarly journals Nodes, paranodes and neuropathies

2017 ◽  
Vol 89 (1) ◽  
pp. 61-71 ◽  
Author(s):  
Janev Fehmi ◽  
Steven S Scherer ◽  
Hugh J Willison ◽  
Simon Rinaldi
Keyword(s):  
Peripheral Nerves ◽  
Clinical Importance ◽  
Specific Cell ◽  
Peripheral Neuropathies ◽  
Autoimmune Neuropathy ◽  
Basic Understanding ◽  
Clinical Variants ◽  
Inflammatory Neuropathies ◽  
The Common ◽  
Treatment Responsiveness

This review summarises recent evidence supporting the involvement of the specialised nodal and perinodal domains (the paranode and juxtaparanode) of myelinated axons in the pathology of acquired, inflammatory, peripheral neuropathies.The identification of new target antigens in the inflammatory neuropathies heralds a revolution in diagnosis, and has already begun to inform increasingly targeted and individualised therapies. Rapid progress in our basic understanding of the highly specialised nodal regions of peripheral nerves serves to strengthen the links between their unique microstructural identities, functions and pathologies. In this context, the detection of autoantibodies directed against nodal and perinodal targets is likely to be of increasing clinical importance. Antiganglioside antibodies have long been used in clinical practice as diagnostic serum biomarkers, and associate with specific clinical variants but not to the common forms of either acute or chronic demyelinating autoimmune neuropathy. It is now apparent that antibodies directed against several region-specific cell adhesion molecules, including neurofascin, contactin and contactin-associated protein, can be linked to phenotypically distinct peripheral neuropathies. Importantly, the immunological characteristics of these antibodies facilitate the prediction of treatment responsiveness.

scholarly journals Searching for New Biomarkers of Renal Diseases through Proteomics

2012 ◽  
Vol 58 (2) ◽  
pp. 353-365 ◽  
Author(s):  
Ana Konvalinka ◽  
James W Scholey ◽  
Eleftherios P Diamandis
Keyword(s):  
Mass Spectrometry ◽  
Prognostic Markers ◽  
Renal Diseases ◽  
Sample Collection ◽  
Technological Advances ◽  
Regulatory Bodies ◽  
New Biomarkers ◽  
Study Designs ◽  
Treatment Responsiveness ◽  
Proteomic Methods

Abstract BACKGROUND Technological advances have resulted in a renaissance of proteomic studies directed at finding markers of disease progression, diagnosis, or responsiveness to therapy. Renal diseases are ideally suited for such research, given that urine is an easily accessible biofluid and its protein content is derived mainly from the kidney. Current renal prognostic markers have limited value, and renal biopsy remains the sole method for establishing a diagnosis. Mass spectrometry instruments, which can detect thousands of proteins at nanomolar (or even femtomolar) concentrations, may be expected to allow the discovery of improved markers of progression, diagnosis, or treatment responsiveness. CONTENT In this review we describe the strengths and limitations of proteomic methods and the drawbacks of existing biomarkers, and provide an overview of opportunities in the field. We also highlight several proteomic studies of biomarkers of renal diseases selected from the plethora of studies performed. SUMMARY It is clear that the field of proteomics has not yet fulfilled its promise. However, ongoing efforts to standardize sample collection and preparation, improve study designs, perform multicenter validations, and create joint industry–regulatory bodies offer promise for the recognition of novel molecules that could change clinical nephrology forever.

scholarly journals May be Urinary Excretion of α2-macroglobulin (MW 720 kDa) a Proteinuric Marker of Podocytopathy? Insight from Analysis of 204 Patients with Glomerulonephritis (GN) and Nephrotic Syndrome, 177 with Functional Outcome

2021 ◽  
Vol 8 (3) ◽  
pp. 01-06
Author(s):  
Claudio Bazzi
Keyword(s):  
Nephrotic Syndrome ◽  
Clinical Practice ◽  
Urinary Excretion ◽  
Functional Outcome ◽  
Clinical Significance ◽  
Α2 Macroglobulin ◽  
Progression Risk ◽  
Treatment Responsiveness

Background: In IgAN with cellular crescents (CIgAN) urinary excretion of α2-macroglobulin (α2m/C, MW 720 kDa) may be a marker of podocytes damage induced by crescents. The purpose of the study was the evaluation of the clinical significance of α2m/C excretion in 177 patients with glomerulonephritis (GN), nephrotic syndrome (NS) and functional outcome. Methods: In all 177 patients α2m/C excretion was measured; the patients were divided in 2 groups: α2mC=0 (n. 72) and α2m/C >0 (n. 105); for each group were assessed the outcomes considered in combination: Remission & persistent nephrotic syndrome (PNS) with long lasting NRF designed “Remission & NRF”; ESRD & eGFR < 50% & PNS with CRF designed “Progression and progression risk”. Results: In 72 patients with α2m/C=0 “Remission & NRF” was 78% and “Progression & progression risk” was 22%; in 105 patients with α2m/C>0 “remission & NRF” was 52% and “Progression & progression risk” was 48%. “Remission & NRF” in each GN type with α2m/C=0 was: 100% in MCD and LN; 82%, 79%, 67% in FSGS, IMN, MPGN; in α2m/C>0 “Progression and progression risk” was 0%, 38%, 46%, 54%, 56%, 85% in MCD, LN, IMN, MPGN, FSGS, CIgAN with cellular crescents, respectively. Conclusion: Urinary excretion of α2m is a very simple marker available in all clinical practice laboratories, marker of damage of podocytes at least in CIgAN and LN with crescents and marker of GFB damage in different GN types and useful to predict outcome and treatment responsiveness.

scholarly journals Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors

Cells ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 968 ◽  
Author(s):  
Katia Scotlandi ◽  
Claudia Maria Hattinger ◽  
Evelin Pellegrini ◽  
Marco Gambarotti ◽  
Massimo Serra
Keyword(s):  
Therapeutic Strategies ◽  
Common Variants ◽  
Primary Tumors ◽  
Primary Bone Tumors ◽  
Road Map ◽  
Tumors Of Bone ◽  
Primary Bone ◽  
Novel Therapeutic Strategies ◽  
Treatment Responsiveness ◽  
Selection Of

Osteosarcoma, Ewing sarcoma and chondrosarcoma are rare diseases but the most common primary tumors of bone. The genes directly involved in the sarcomagenesis, tumor progression and treatment responsiveness are not completely defined for these tumors, and the powerful discovery of genetic analysis is highly warranted in the view of improving the therapy and cure of patients. The review summarizes recent advances concerning the molecular and genetic background of these three neoplasms and, of their most common variants, highlights the putative therapeutic targets and the clinical trials that are presently active, and notes the fundamental issues that remain unanswered. In the era of personalized medicine, the rarity of sarcomas may not be the major obstacle, provided that each patient is studied extensively according to a road map that combines emerging genomic and functional approaches toward the selection of novel therapeutic strategies.

The End of Life Within Social Work Literature: A Conceptual Review

2019 ◽  
pp. 003022281983565 ◽  
Author(s):  
Margaret M. Holland ◽  
Stephanie Grace Prost
Keyword(s):  
Social Work ◽  
Lived Experience ◽  
End Of Life ◽  
Meta Analysis ◽  
Work Practice ◽  
Social Work Practice ◽  
Death Process ◽  
Eligibility Criteria ◽  
Social Work Practitioners ◽  
Treatment Responsiveness

The current conceptual review sought to identify and describe how the end of life was conceptualized and operationalized in top-ranking, peer-reviewed social work journals considering the highly individualized and multidimensional experience of dying put forth by modern scholars and social work practitioners. An iterative content analysis of included articles ( N = 103) revealed six themes within reported definitions and four themes within eligibility criteria. Definitions ( n = 66) related to treatment responsiveness, the death process, dying, prognosis, admission to specific services, and old age. Eligibility criteria ( n = 18) related to proxy assessment, diagnosis, prognosis, and functional ability assessments. Over one-third of included articles did not define what was meant by the end of life (36%; n = 37) and the majority did not include eligibility criteria (83%; n = 85). In conclusion, the complex lived experience of dying was not manifest within included articles raising important implications for research (e.g., measurement, meta-analysis) and social work practice (viz. service eligibility).

Sign in / Sign up

Export Citation Format

Share Document